SAG1 and TLR-5 ligand |
|
Vaxjo ID |
407 |
|
Vaccine Adjuvant Name |
SAG1 and TLR-5 ligand |
|
Alternative Names |
SAG1 may also be referred to as Surface Antigen 1. The TLR-5 ligand used in the study is FliC. |
|
Adjuvant VO ID |
VO_0005701
|
|
Description |
The vaccine is a DNA vaccine that encodes the SAG1 protein of Toxoplasma gondii and includes a gene sequence encoding FliC from Salmonella typhimurium, which acts as a genetic adjuvant. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Second Host Species for Testing |
Pig |
|
Structure |
The vaccine consists of a plasmid encoding the SAG1 protein and a plasmid encoding the FliC protein, which is a TLR-5 agonist. |
|
Storage |
The plasmid DNA should be stored at −20 °C until use. |
|
Preparation |
The vaccine is prepared by cloning the SAG1 and FliC genes into a eukaryotic expression vector (pVAX1), followed by transfection into CHO cells to express the proteins. |
|
Function |
Toxoplasma gondii is an obligate intracellular, protozoan that causes a high incidence of serious zoonotic parasitic disease in humans. In the present study the immune-protective efficacy of a DNA vaccine encoding SAG1 in combination with a gene sequence encoding FliC of Salmonella typhimurium (Toll-like receptor 5 agonist) was evaluated against acute T. gondii infection in mice. |
| References |
Maraghi et al., 2019: Maraghi S, Ghadiri AA, Tavalla M, Shojaee S, Abdizadeh R. Evaluation of immunogenicity and protective effect of DNA vaccine encoding surface antigen1 (SAG1) of Toxoplasma gondii and TLR-5 ligand as a genetic adjuvant against acute toxoplasmosis in BALB/c mice. Biologicals : journal of the International Association of Biological Standardization. 2019; 62; 39-49. [PubMed: 31610951].
|
